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Abstract
Background: While the protective effects of sickle cell trait (HbAS) against severe malaria and
the resulting survival advantage are well known, the impact on the physical development in young
children remains unclear. This study was aimed to investigate the relationship between HbS
carriage and stunting in children below two years of age in a cohort from the Ashanti Region,
Ghana.
Methods: 1,070 children were recruited at three months of age and followed-up for 21 months
with anthropometric measurements performed every three months. Incidence rate ratios with 95%
confidence intervals were calculated by Poisson regression to estimate the association of β-globin
genotypes with the number of malaria episodes. Odds ratios (OR) were calculated for the
association between the occurrence of β-globin genotypes and/or malaria episodes and stunting.
The age-dependent between-group and within-group effects for the β-globin genotypes were
assessed by population-averaged models estimated by generalized estimation equation with
autoregressive correlation structure.
Results: Analyses showed a significantly lower age-dependent risk of stunting (OR 0.56; 95% CI
0.33–0.96) in carriers of the HbAS genotype (n = 102) in comparison to those with HbAA (n =
692). This effect was restricted to children who experienced malaria episodes during the
observation period suggesting that the beneficial effect of the β-globin HbS variant on the incidence
of stunting is closely linked to its protection from mild malaria episodes.
Conclusion: The lower risk of chronic malnutrition in early childhood, mediated by protection
against mild malaria episodes, may contribute to the survival advantage of HbAS carriers in areas
of high malaria transmission.
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Background
There is much epidemiological evidence that sickle cell
trait decreases the risk for all manifestations of severe
malaria and that this protective effect has caused a bal-
anced polymorphism of the sickle cell mutation (HbS) in
malaria endemic regions [1]. In addition to protection
against severe malaria, HbS has also been shown to
exhibit some level of protection against mild malaria [2].
The importance of this observation for the survival advan-
tage of individuals with HbAS remains unclear [3].
Repeated malaria episodes in early childhood can impair
a child's development and induce malnutrition [4-6].
Stunting (length/height-for-age z-score < -2) in early
childhood, as an indicator of chronic malnutrition, is a
common condition in African children and one of the
main determinants of childhood morbidity and mortality
[7]. It has also been demonstrated, that stunting is related
to poor cognitive performance later on in life and has a
negative effect on adult health and human capital [8,9].
So far, most studies on the effect of HbAS on physical
development were performed in areas without malaria
transmission. In the majority of these studies no signifi-
cant differences between individuals with the HbAA and
HbAS genotype were found [10,11], while some investiga-
tors found a slight impairment of development in HbAS
carriers [12]. Results of the only study performed in an
area of low malaria endemicity also showed no protection
of HbAS carriers against stunting [4]. The hypothesis of
the present study was, that in areas with high malaria
transmission, HbAS may, through protection against
malaria, also confer protection against stunting in young
children.
Methods
In the frame of a trial on Intermittent Preventive Treat-
ment in infants (IPTi), conducted from January 2003 to
September 2005, a cohort of 1,070 children from a rural
district in the Ashanti Region of Ghana was recruited at
the age of three months and followed-up monthly until
two years of age. On each visit a clinical examination was
performed, a standardized medical history taken and par-
asite density measured. The length of each child was
assessed at recruitment and subsequently in three-
monthly intervals, with measurements performed on the
same standardized length board for all children. Details
on the study area, study group and procedures have been
published elsewhere [13,14]. A malaria episode was
defined as body temperature > 38°C or a history of fever
in the preceding 48 h and a parasite density of more than
500 parasites/μl. Stunting was defined as a length/height-
for-age z-score of less than -2 according to WHO (moder-
ate and severe stunting combined) [15]. DNA preparation
and genotyping of the β-globin gene were performed
according to standardized protocols as described else-
where [16].
Statistical analyses were performed with STATA (version
10.0, StataCorp, USA). Only children with HbAA or HbAS
genotype and with at least six completed anthropometric
measurements were considered for the analyses. Missing
values for anthropometric data between two existing fol-
low-up visits were interpolated by calculating the mean of
the two flanking visits (in total 5883 anthropometric
measurements and 342 interpolated values). P values
below 0.05 were considered significant. Incidence rate
ratios (IRR) with 95% confidence intervals (CI) were cal-
culated by Poisson regression to estimate the association
of β-globin genotypes with the number of malaria epi-
sodes. Odds ratios (OR) were calculated for the associa-
tion between the occurrence of β-globin genotypes and/or
malaria episodes and stunting. The age-dependent
between-group and within-group effects for the β-globin
genotypes were assessed by population-averaged models
estimated by generalized estimation equation (GEE) with
autoregressive correlation structure of order 5 and
assumption of binomial variable distribution. Autoregres-
sion was used to account for intra-individual age-depend-
ency of anthropometric measurements and the most
appropriate autoregression order was assessed by correla-
tion matrices. Resulting coefficients were log-transformed
and given as ORs with CI to estimate the risks for stunting
at three-monthly cross-sectional time-series.
Results
Out of the 1,070 children recruited, 794 children were
included in the analyses as they were carriers of the HbAA
or HbAS genotype and had completed at least six anthro-
pometric measurements. A total of 692 children were
HbAA homozygotes while 102 children were carriers of
HbAS (Table 1). At recruitment (three months of age) 4%
of all children in the study group were stunted, while at
the end of the follow-up period (two years of age) this
proportion had increased to 20%. In children who were
not stunted at recruitment, HbAS carriers had a 58%
decreased risk of being stunted at two years of age in com-
parison to HbAA carriers (OR 0.42; CI 0.20–0.86; p =
0.016). GEE analyses with autoregression showed that
children with the HbAS genotype had a 44% lower age-
dependent risk of stunting during the first two years of life
(OR 0.56; CI 0.33–0.96; p = 0.034). A sub-group analysis
showed that the effect was restricted to children with at
least one episode of malaria (OR 0.49; CI 0.25–0.93; p =
0.03). In contrast, children without any malaria episodes
HbAS carriers were not protected against stunting (OR
0.84; CI 0.33–2.15; p = 0.71) (Figure 1).
In addition to being protected against stunting, HbAS car-
riers in this study were also protected against mild malariaMalaria Journal 2009, 8:16 http://www.malariajournal.com/content/8/1/16
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episodes (IRR 0.82; CI 0.69–0.96; p = 0.017). In order to
analyze a direct effect of malaria episodes on stunting, the
ORs for the risk of stunting at the end of the study period
were calculated only for children who were not stunted at
recruitment. Children with two or more episodes of
malaria during the study period had an increased risk of
becoming stunted at two years of age compared to chil-
dren with zero or one episode (OR 1.71; CI 1.17–2.51; p
= 0.006). Other factors with reported influence on stunt-
ing (e.g. breastfeeding, birth-weight, ethnic group,
mother's literacy, mosquito nets/screens and financial sta-
tus) and other genetic hemoglobin disorders (α+-tha-
lassemia) were tested for effect modification but no
influence on the effect of HbAS and malaria on stunting
was detected. There was also no effect modification by the
study-arm (IPTi vs. placebo).
Discussion
While the protective effect of HbAS on the risk of severe
malaria is well known [2,3], protection of HbAS carriers
against mild malaria episodes and a subsequent effect on
general child health remains unclear [17]. This study was
aimed to assess the effect of HbAS on mild malaria and to
identify a possible effect on childhood development. As
expected, HbAS carriers were significantly protected
against mild malaria episodes in the study presented here.
However, when compared to HbAA carriers, HbAS carriers
also demonstrated a lower risk of stunting during the first
two years of life. Such a direct association between sickle
cell trait and stunting has not been reported before. Since
malaria itself has been positively associated with stunting
in the past [4-6], it seems possible that a protective effect
of the sickle cell trait against malaria could explain the
decreased risk of HbAS carriers for stunting. The fact that
malaria was also found to increase the risk of being
stunted at two years of age in this study further supports
this hypothesis. Notably, previous studies on the relation-
ship between HbAS and early childhood development
that found no protection of HbAS against stunting were
all conducted in areas without or with only low malaria
transmission [4,10-12]. A sub-group analysis of children
without any malaria during the study period showed no
protective effect of HbAS carriers against stunting. This
also indicates that an effect of HbAS on stunting may only
be exhibited in populations highly exposed to malaria
and may explain why this effect was not detected in earlier
studies. A further reason why previous studies failed to
find an association might be the age range under study.
The protective effect of HbAS is greatest at young age and
becomes less distinct later in life [3]. While this study
focuses on children between three months and two years
of age, other studies also included older children. Due to
the intensive follow-up scheme and medical interventions
in case of illness as well as regular substitution of iron,
folic acid, vitamin A and zinc, fewer children than
expected were stunted. Substitution of micronutrients and
vitamins did not differ between the two groups and is
therefore unlikely to have confounded the results. The
lower incidence of stunting however may have lead to an
indifferential error and an underestimation of the protec-
tive effect of HbAS against stunting. A further limitation
could be a follow-up bias due to the restriction of the
analysis to children who were available for six anthropo-
metric measurements. This bias, however, might be mini-
mal since only 19 children were lost to follow-up due to
early death.
Relationship between stunting and age in children with and  without malaria episodes Figure 1
Relationship between stunting and age in children 
with and without malaria episodes. Proportion of chil-
dren stunted with increasing age stratified for b-globin geno-
types HbAA (dots and solid line) and HbAS (crosses and 
dashed line). GEE analyses with adjustment for within-group, 
between-group effects and age-dependency were performed 
with autoregressive correlation structure of order 5 and 
assumption of binomial variable distribution. A, children 
without malaria episodes; no significant protective effect of 
HbAS (OR 0.84; CI 0.33–2.15; p = 0.71). B, children with at 
least one episode of malaria; 51% lower risk of stunting (OR 
0.49; CI 0.25–0.93; p = 0.03).
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Conclusion
Young children with sickle cell trait (HbAS) have a lower
risk of stunting in an area with high malaria transmission,
most likely mediated through protection against mild
malaria. Since stunting in early years is known to be a
strong risk factor for morbidity and mortality and consid-
ering the high incidence of mild malaria, it seems proba-
ble that protection against stunting contributes essentially
to the survival advantage of HbAS carriers.
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Authors' contributions
BK collected data, performed statistical analyses and wrote
the first draft of the manuscript. SE contributed to the
Table 1: Characteristics of study participants at recruitment
β-globin genotypea
HbAA (n = 692) HbAS (n = 102)
Mean length/height-for-age z-score (sd)b 0.31 (± 1.22) 0.33 (± 1.11)
Clinical malaria (%)
No 678 (98.1) 101 (98.0)
Yes 13 (1.9) 1 (1.0)
Breastfeeding (%)
Exclusively 594 (86.0) 94 (92.2)
Non-exclusively 97 (14.0) 8 (7.8)
Mean birth-weight (sd), gc 2996 (± 471) 3085 (± 366)
Ethnic group (%)
Ashanti 615 (89.4) 88 (86.3)
Northerner 73 (10.6) 14 (13.7)
Mother's literacy (%)
Literate 620 (90.6) 91 (91.0)
Illiterate 64 (9.4) 9 (9.0)
Mosquito protection (%)
None 290 (44.1) 54 (57.4)
Bed netsd 234 (35.6) 29 (30.9)
Screens 134 (20.4) 11 (11.7)
Financial situation (%)
Good 458 (70.5) 66 (70.2)
Poor 192 (29.5) 28 (29.8)
α+-thalassemia (%)
wild type 506 (74.3) 76 (75.2)
heterozygotes 159 (23.4) 22 (21.8)
homozygote deletion 16 (2.3) 3 (3.0)
Study arm (%)
IPTi 345 (49.9) 50 (49.0)
Placebo 347 (50.1) 52 (51.0)
sd, standard deviation.
a missing values possible due to incomplete or unvalidated parameters.
b n = 794.
c n = 547.
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